Bouchra Amine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bouchra Amine has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Najia Hajjaj-Hassouni
Mohammed VI University of Health Sciences (UM6SS)
23 shared publications - Samira Rostom
Department of Rheumatology, El Ayachi Hospital, University Hospital of Rabat-Sale, Sale, Morocco
13 shared publications - Rachid Bahiri
Rheumatology A Department, El Ayachi Hospital, CHU Rabat-Salé, Salé, Morocco
8 shared publications - Redouane Abouqal
Biostatistics Laboratory, Clinical Epidemiology Research. Faculty of Medicine and Pharmacy Mohammed V University in Rabat Rabat Morocco
7 shared publications Karima Benbouazza
University Hospital of Rabat-Sale
5 shared publications- Imane El Binoune
Rheumatology Department A, El Ayachi Hospital, CHU Rabat-Salé, Rabat, Morocco
4 shared publications
Latest Publications
- 28 September 2026
- Published by Bentham Science Publishers Ltd. in Current Rheumatology Reviews
- Vol. 22, 1-11
Multimorbidity and Hospital-related Outcomes in Patients with Rheumatoid Arthritis: A Cross-sectional Study
Introduction: Multimorbidity is frequent in rheumatoid arthritis (RA) and is associated with increased mortality, impaired quality of life, and complex clinical management. However, its association with hospitalization characteristics, particularly hospital length of stay and reasons for admission, remains insufficiently characterized. Methods: We conducted a five-month cross-sectional study (February to July 2024) in a tertiary university hospital, including adult patients diagnosed with rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria. Multimorbidity was defined as the presence of at least two chronic comorbid conditions (CHCs), and patients were stratified into two categories: multimorbid (MMG) and non-multimorbid (N-MMG) groups. Data collected included demographic characteristics, clinical features, laboratory parameters, and imaging findings. Functional impairment was assessed using the Health Assessment Questionnaire (HAQ). Results: The study included 126 individuals with a mean age of 56.6 ± 13.4 years, of whom 84.9% were female. Multimorbidity was present in 52.4% of cases. Patients in the MMG were significantly older than those in the N-MMG (62.1 ± 9.9 vs 50.5 ± 14.2 years, p < 0.001). They also had significantly higher disease activity (DAS28, p < 0.001) and more impaired functional status as measured by HAQ (p < 0.001). Length of hospital stay was significantly longer in the multimorbid group. A hospital stay of 14 days or more was observed in 31% of MMG patients compared with 10.3% in the N-MMG cohort. Multivariate logistic regression analysis revealed that increasing age (OR = 1.11, 95% CI: 1.05-1.17, p < 0.001) and current corticosteroid use (OR = 4.73, 95% CI: 1.73-12.95, p = 0.002) were independently associated with multimorbidity. In addition, multimorbidity remained independently associated with prolonged hospitalization after adjustment for age, disease duration, disease activity, and corticosteroid use (adjusted OR = 3.42, 95% CI: 1.36-8.60; p = 0.009). Discussion: In this study, multimorbidity was associated with greater clinical complexity among hospitalized patients with RA and with less favorable hospital-related outcomes, particularly longer hospitalization duration. The higher disease activity and poorer functional status observed among multimorbid patients may partly explain the longer hospital stays observed. Conclusion: Our findings indicate that multimorbidity is associated with a more complex clinical profile in hospitalized patients with rheumatoid arthritis and with poorer hospital-related outcomes, particularly prolonged length of stay. These associations may partly reflect the higher disease activity and greater functional impairment observed among multimorbid patients.
- 28 September 2026
- Published by Bentham Science Publishers Ltd. in Current Rheumatology Reviews
- Vol. 22, 1-11
Multimorbidity and Hospital-related Outcomes in Patients with Rheumatoid Arthritis: A Cross-sectional Study
Introduction: Multimorbidity is frequent in rheumatoid arthritis (RA) and is associated with increased mortality, impaired quality of life, and complex clinical management. However, its association with hospitalization characteristics, particularly hospital length of stay and reasons for admission, remains insufficiently characterized. Methods: We conducted a five-month cross-sectional study (February to July 2024) in a tertiary university hospital, including adult patients diagnosed with rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria. Multimorbidity was defined as the presence of at least two chronic comorbid conditions (CHCs), and patients were stratified into two categories: multimorbid (MMG) and non-multimorbid (N-MMG) groups. Data collected included demographic characteristics, clinical features, laboratory parameters, and imaging findings. Functional impairment was assessed using the Health Assessment Questionnaire (HAQ). Results: The study included 126 individuals with a mean age of 56.6 ± 13.4 years, of whom 84.9% were female. Multimorbidity was present in 52.4% of cases. Patients in the MMG were significantly older than those in the N-MMG (62.1 ± 9.9 vs 50.5 ± 14.2 years, p < 0.001). They also had significantly higher disease activity (DAS28, p < 0.001) and more impaired functional status as measured by HAQ (p < 0.001). Length of hospital stay was significantly longer in the multimorbid group. A hospital stay of 14 days or more was observed in 31% of MMG patients compared with 10.3% in the N-MMG cohort. Multivariate logistic regression analysis revealed that increasing age (OR = 1.11, 95% CI: 1.05-1.17, p < 0.001) and current corticosteroid use (OR = 4.73, 95% CI: 1.73-12.95, p = 0.002) were independently associated with multimorbidity. In addition, multimorbidity remained independently associated with prolonged hospitalization after adjustment for age, disease duration, disease activity, and corticosteroid use (adjusted OR = 3.42, 95% CI: 1.36-8.60; p = 0.009). Discussion: In this study, multimorbidity was associated with greater clinical complexity among hospitalized patients with RA and with less favorable hospital-related outcomes, particularly longer hospitalization duration. The higher disease activity and poorer functional status observed among multimorbid patients may partly explain the longer hospital stays observed. Conclusion: Our findings indicate that multimorbidity is associated with a more complex clinical profile in hospitalized patients with rheumatoid arthritis and with poorer hospital-related outcomes, particularly prolonged length of stay. These associations may partly reflect the higher disease activity and greater functional impairment observed among multimorbid patients.
- Open Access
- 12 July 2026
- Published by Springer Nature
- p. 171-188
Rheumatic Diseases in Morocco
Morocco has approximately 400 registered rheumatologists serving a population of 37.7 million, corresponding to a low workforce density of about one rheumatologist per 100,000 inhabitants. This shortage is particularly concerning in the context of population aging and the anticipated increase in the burden of rheumatic diseases. The Moroccan health system includes both public and private sectors, with the private sector expanding rapidly, particularly in regions such as Casablanca-Settat and Rabat-Salé-Kénitra. Rheumatology practice is represented nationally by the Moroccan Society of Rheumatology (SMR), which brings together specialists and practitioners interested in musculoskeletal diseases. The SMR plays a central role in advancing clinical practice, education, research, and advocacy and has progressively strengthened its organizational structure and strategic capacity. Key initiatives include training programs in musculoskeletal ultrasound; the Moroccan Registry of Biological Therapies in Rheumatoid Diseases (RBSMR), one of the earliest registries of its kind in Africa; patient education programs to improve long-term disease management; and national public awareness campaigns. Despite substantial progress over the past two decades, important challenges remain. Priority areas for future development include increasing the rheumatology workforce, establishing centers of excellence, and expanding research programs tailored to the specific epidemiological and health care needs of the Moroccan population.
- 12 July 2026
- Published by Springer Nature
- p. 171-188
Open AccessRheumatic Diseases in Morocco
Morocco has approximately 400 registered rheumatologists serving a population of 37.7 million, corresponding to a low workforce density of about one rheumatologist per 100,000 inhabitants. This shortage is particularly concerning in the context of population aging and the anticipated increase in the burden of rheumatic diseases. The Moroccan health system includes both public and private sectors, with the private sector expanding rapidly, particularly in regions such as Casablanca-Settat and Rabat-Salé-Kénitra. Rheumatology practice is represented nationally by the Moroccan Society of Rheumatology (SMR), which brings together specialists and practitioners interested in musculoskeletal diseases. The SMR plays a central role in advancing clinical practice, education, research, and advocacy and has progressively strengthened its organizational structure and strategic capacity. Key initiatives include training programs in musculoskeletal ultrasound; the Moroccan Registry of Biological Therapies in Rheumatoid Diseases (RBSMR), one of the earliest registries of its kind in Africa; patient education programs to improve long-term disease management; and national public awareness campaigns. Despite substantial progress over the past two decades, important challenges remain. Priority areas for future development include increasing the rheumatology workforce, establishing centers of excellence, and expanding research programs tailored to the specific epidemiological and health care needs of the Moroccan population.
- Open Access
- 1 December 2025
- Published by Springer Nature in BMC Rheumatology
- Vol. 10 (1)
Use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis receiving biotherapy and associated factors: a prospective cohort study
The objectives of this study were to evaluate NSAID use over time in patients with axial spondyloarthritis (axSpA) receiving biologic therapy, to determine
- 1 December 2025
- Published by Springer Nature in BMC Rheumatology
- Vol. 10 (1)
Open AccessUse of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis receiving biotherapy and associated factors: a prospective cohort study
The objectives of this study were to evaluate NSAID use over time in patients with axial spondyloarthritis (axSpA) receiving biologic therapy, to determine
- Open Access
- 1 July 2025
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 33 (3) , 227-231
Intraosseous migration of calcific supraspinatus tendonitis: a case report
Chaimae Charoui, M.D., Imane El Binoune, M.D., Nada Jaouad, M.D., Bouchra Amine, Ph.D., Rachid Bahiri, Ph.D.. J Rheum Dis -0001;0:. https://doi.org/10.4078/jrd.2025.0037
- 1 July 2025
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 33 (3) , 227-231
Open AccessIntraosseous migration of calcific supraspinatus tendonitis: a case report
Chaimae Charoui, M.D., Imane El Binoune, M.D., Nada Jaouad, M.D., Bouchra Amine, Ph.D., Rachid Bahiri, Ph.D.. J Rheum Dis -0001;0:. https://doi.org/10.4078/jrd.2025.0037
- Open Access
- 20 June 2025
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 63 (3) , 166-173
Insights into diagnosis and treatment of fibromyalgia among Moroccan rheumatologists: a cross sectional online survey
Introduction: This study outlines the diagnostic and therapeutic approaches – both pharmacological and non-pharmacological – used by Moroccan rheumatologists in managing fibromyalgia (FM). It also addresses other key aspects, such as assessing the psychosocial context of patients and referring them to other medical specialties.Material and methods: A descriptive cross-sectional study was conducted using a survey designed to assess the management approach of Moroccan rheumatologists towards FM. The survey was carried out anonymously.Results: Out of 275 rheumatologists, 140 responded to the questionnaire (with a total of approximately 450 rheumatologists in Morocco). Ninety-nine percent (n = 139) reported encountering FM patients in their practice. Diagnosis of FM was predominantly based on clinical assessment without a scoring system (n = 66; 47%), while 20.7% (n = 29) used the FIRST score. A substantial proportion (70%) of participants requested biological and imaging workups despite apparent FM, with 92% (n = 129) opting for an inflammatory workup. Regarding the treatment aspect, paracetamol was the first-line analgesic prescribed by 58% (n = 81), followed by tramadol (n = 43; 30.9%). Pregabalin was the most commonly prescribed first-line treatment (n = 37; 27.4%), with antidepressants being the second-line choice in 35.8% (n = 42). Non-pharmacological treatments such as physical therapy, therapeutic education, and psychotherapy were the most highly recommended. Nearly all rheumatologists (n = 131; 93.6%) emphasized the need for multidisciplinary management for FM patients, often referring them to psychiatrists either alone or in conjunction with other specialists.Conclusions: Diagnosing and treating FM presents significant challenges. This survey sheds light on the diverse approaches adopted by Moroccan rheumatologists towards managing patients with FM, emphasizing the importance of multidisciplinary care in addressing the complex needs of these patients.
- 20 June 2025
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 63 (3) , 166-173
Open AccessInsights into diagnosis and treatment of fibromyalgia among Moroccan rheumatologists: a cross sectional online survey
Introduction: This study outlines the diagnostic and therapeutic approaches – both pharmacological and non-pharmacological – used by Moroccan rheumatologists in managing fibromyalgia (FM). It also addresses other key aspects, such as assessing the psychosocial context of patients and referring them to other medical specialties.Material and methods: A descriptive cross-sectional study was conducted using a survey designed to assess the management approach of Moroccan rheumatologists towards FM. The survey was carried out anonymously.Results: Out of 275 rheumatologists, 140 responded to the questionnaire (with a total of approximately 450 rheumatologists in Morocco). Ninety-nine percent (n = 139) reported encountering FM patients in their practice. Diagnosis of FM was predominantly based on clinical assessment without a scoring system (n = 66; 47%), while 20.7% (n = 29) used the FIRST score. A substantial proportion (70%) of participants requested biological and imaging workups despite apparent FM, with 92% (n = 129) opting for an inflammatory workup. Regarding the treatment aspect, paracetamol was the first-line analgesic prescribed by 58% (n = 81), followed by tramadol (n = 43; 30.9%). Pregabalin was the most commonly prescribed first-line treatment (n = 37; 27.4%), with antidepressants being the second-line choice in 35.8% (n = 42). Non-pharmacological treatments such as physical therapy, therapeutic education, and psychotherapy were the most highly recommended. Nearly all rheumatologists (n = 131; 93.6%) emphasized the need for multidisciplinary management for FM patients, often referring them to psychiatrists either alone or in conjunction with other specialists.Conclusions: Diagnosing and treating FM presents significant challenges. This survey sheds light on the diverse approaches adopted by Moroccan rheumatologists towards managing patients with FM, emphasizing the importance of multidisciplinary care in addressing the complex needs of these patients.
- 26 June 2021
- Published by Springer Nature in Rheumatology International
- Vol. 41 (9) , 1625-1631
Prevalence of latent tuberculosis before biotherapy initiation in rheumatoid arthritis and spondyloarthritis: data from the Moroccan biotherapy registry
Before the initiation of biotherapy in the treatment of rheumatic diseases, it is highly recommended for the patients to be screened for latent tuberculosis infection (LTBI). The objective of this study is to identify the prevalence of LTBI among patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) before the initiation of biologic therapy in the Moroccan biotherapy registry (RBSMR). A cross sectional study was conducted using the baseline data of the Moroccan biotherapy registry. Tuberculin skin test or IGRA test or both tests were done before starting anti-TNF treatment for screening LTBI. The comparisons between positive and negative LTBI patients according to rheumatic disease were examined using categorical comparisons. 259 patients were included in this study.94 patients had RA and 165 had SpA. The mean age of the RA patients was 50.49 ± 11.82 years with a majority of females (84%). The mean age for the SpA patients was 36 ± 13.7 years with a majority of males (67.3%). The prevalence of LTBI in the RBSMR was 21.6%. This prevalence was at 24.8% in SpA patients, while it was at 15.9% for RA patients. After the comparison between positive and negative LTBI patients according to rheumatic disease, no demographic, clinical, or therapeutic characteristics were statistically associated with LTBI. This study found that in an endemic TB country like Morocco, a high prevalence of patients with SpA and RA had LTBI, and that RA patients had a lower prevalence than SpA patients.
- 26 June 2021
- Published by Springer Nature in Rheumatology International
- Vol. 41 (9) , 1625-1631
Prevalence of latent tuberculosis before biotherapy initiation in rheumatoid arthritis and spondyloarthritis: data from the Moroccan biotherapy registry
Before the initiation of biotherapy in the treatment of rheumatic diseases, it is highly recommended for the patients to be screened for latent tuberculosis infection (LTBI). The objective of this study is to identify the prevalence of LTBI among patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) before the initiation of biologic therapy in the Moroccan biotherapy registry (RBSMR). A cross sectional study was conducted using the baseline data of the Moroccan biotherapy registry. Tuberculin skin test or IGRA test or both tests were done before starting anti-TNF treatment for screening LTBI. The comparisons between positive and negative LTBI patients according to rheumatic disease were examined using categorical comparisons. 259 patients were included in this study.94 patients had RA and 165 had SpA. The mean age of the RA patients was 50.49 ± 11.82 years with a majority of females (84%). The mean age for the SpA patients was 36 ± 13.7 years with a majority of males (67.3%). The prevalence of LTBI in the RBSMR was 21.6%. This prevalence was at 24.8% in SpA patients, while it was at 15.9% for RA patients. After the comparison between positive and negative LTBI patients according to rheumatic disease, no demographic, clinical, or therapeutic characteristics were statistically associated with LTBI. This study found that in an endemic TB country like Morocco, a high prevalence of patients with SpA and RA had LTBI, and that RA patients had a lower prevalence than SpA patients.
- 26 September 2020
- Published by Springer Nature in Current Clinical Microbiology Reports
- Vol. 7 (4) , 124-132
Reactive Arthritis: Update
Purpose of Review The aim of this paper is to provide an overview about reactive arthritis, with an update regarding pathophysiology and therapeutic approach of the disease, outlining the clinical features and diagnostic approach, based on recent literature review. Recent Findings Reactive arthritis is considered to be part of the spectrum of the spondyloarthritis. Its epidemiology is changing worldwide due to several reasons, among them are as follows: different diagnosis approach and clinical presentations, different grades of infection, microbiome changes, etc. The understanding of pathophysiological models is challenging, but recent studies contribute to elucidate the major factors involved in the development of the disease. The management of ReA depends on the triggering agent and the phase of disease, whether it is acute or chronic. Summary The association between the microbiome changes and spondyloarthropathies (ReA) is becoming increasingly evident. The results regarding the biologic treatment on refectory ReA are promising.
- 26 September 2020
- Published by Springer Nature in Current Clinical Microbiology Reports
- Vol. 7 (4) , 124-132
Reactive Arthritis: Update
Purpose of Review The aim of this paper is to provide an overview about reactive arthritis, with an update regarding pathophysiology and therapeutic approach of the disease, outlining the clinical features and diagnostic approach, based on recent literature review. Recent Findings Reactive arthritis is considered to be part of the spectrum of the spondyloarthritis. Its epidemiology is changing worldwide due to several reasons, among them are as follows: different diagnosis approach and clinical presentations, different grades of infection, microbiome changes, etc. The understanding of pathophysiological models is challenging, but recent studies contribute to elucidate the major factors involved in the development of the disease. The management of ReA depends on the triggering agent and the phase of disease, whether it is acute or chronic. Summary The association between the microbiome changes and spondyloarthropathies (ReA) is becoming increasingly evident. The results regarding the biologic treatment on refectory ReA are promising.
- Open Access
- 7 February 2020
- Published by Springer Nature in BMC Rheumatology
- Vol. 4 (1) , 1-5
Two cases of perforated corneal ulcers complicating rheumatoid arthritis treated successfully by biological therapy
Peripheral ulcerative keratitis (PUK) is a severe inflammatory ocular disease that can affect patients with a long history of rheumatoid arthritis (RA). The use of biotherapy has revolutionized the treatment of the RA and has provided encouraging outcomes especially in the treatment of PUK reported in few cases. In this article, we describe the case of two patients with the history of perforated corneal ulcer complicating RA treated successfully by biologic agents. Case 1: A 45-year-old woman was diagnosed for over 17 years with sero-positive RA refractory to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). She had received one cycle of Rituximab with clinical and biological failure. In July 2017, she presented an active RA flare with a painful left eye and a decreased visual acuity. Ocular examination revealed a corneal perforation in the left eye and a pre-perforation in the right eye. She received an emergency bolus of methylprednisolone 1 g/day during three consecutive days and was followed by Infliximab. After thirteen months, Infliximab was effective on the rheumatic disease and on the corneal involvement as it stopped its gradual perforation in the right eye, and stabilized corneal ulcer in the left eye. Case 2: A 68-year-old man had been diagnosed since 2010 with sero-positive RA refractory to csDMARDs complicated in July 2017 by corneal perforation in the right eye. He was hospitalized for his ocular involvement and his active RA. He received an emergency bolus of methylprednisolone 500 mg/day during three consecutive days and was followed by Rituximab. After six months, we observed the stabilization of the right eye corneal damage and the resolution of articular symptoms. Our cases suggest the efficacy of Infliximab (case 1) and Rituximab (case 2) as a treatment of this severe and destructive keratolysis of the cornea complicating an active RA allowing to plan corneal graft. This positive therapeutic response will contribute to increase literature reports of this therapy success.
- 7 February 2020
- Published by Springer Nature in BMC Rheumatology
- Vol. 4 (1) , 1-5
Open AccessTwo cases of perforated corneal ulcers complicating rheumatoid arthritis treated successfully by biological therapy
Peripheral ulcerative keratitis (PUK) is a severe inflammatory ocular disease that can affect patients with a long history of rheumatoid arthritis (RA). The use of biotherapy has revolutionized the treatment of the RA and has provided encouraging outcomes especially in the treatment of PUK reported in few cases. In this article, we describe the case of two patients with the history of perforated corneal ulcer complicating RA treated successfully by biologic agents. Case 1: A 45-year-old woman was diagnosed for over 17 years with sero-positive RA refractory to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). She had received one cycle of Rituximab with clinical and biological failure. In July 2017, she presented an active RA flare with a painful left eye and a decreased visual acuity. Ocular examination revealed a corneal perforation in the left eye and a pre-perforation in the right eye. She received an emergency bolus of methylprednisolone 1 g/day during three consecutive days and was followed by Infliximab. After thirteen months, Infliximab was effective on the rheumatic disease and on the corneal involvement as it stopped its gradual perforation in the right eye, and stabilized corneal ulcer in the left eye. Case 2: A 68-year-old man had been diagnosed since 2010 with sero-positive RA refractory to csDMARDs complicated in July 2017 by corneal perforation in the right eye. He was hospitalized for his ocular involvement and his active RA. He received an emergency bolus of methylprednisolone 500 mg/day during three consecutive days and was followed by Rituximab. After six months, we observed the stabilization of the right eye corneal damage and the resolution of articular symptoms. Our cases suggest the efficacy of Infliximab (case 1) and Rituximab (case 2) as a treatment of this severe and destructive keratolysis of the cornea complicating an active RA allowing to plan corneal graft. This positive therapeutic response will contribute to increase literature reports of this therapy success.
- Open Access
- 5 July 2017
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 11 (1) , 181
Noncontiguous multi-tiered spinal tuberculosis associated with sternal localization: a case report
Tuberculous spondylodiscitis is a frequent localization of tuberculosis. Multi-tiered involvement and an association with sternal localization are rare. We report a case of multi-tiered tuberculous spondylodiscitis with sternal localization in an immunocompetent 41-year-old Arab woman who had inflammatory bilateral sciatica L5 and S1 and a history of low back pain caused by a trauma. Radiography, computed tomography, and a vertebral biopsy were useful for diagnosis. She reacted well to anti-bacillary treatment despite the occurrence of multiple paravertebral and subcutaneous abscesses. The medullar magnetic resonance imaging control performed at 4 months, 12 months, and 1 year after the end of treatment showed a favorable evolution. To avoid the delay of diagnosis, especially in our endemic context, tuberculosis must be evoked usually. This will improve the prognosis of our patients.
- 5 July 2017
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 11 (1) , 181
Open AccessNoncontiguous multi-tiered spinal tuberculosis associated with sternal localization: a case report
Tuberculous spondylodiscitis is a frequent localization of tuberculosis. Multi-tiered involvement and an association with sternal localization are rare. We report a case of multi-tiered tuberculous spondylodiscitis with sternal localization in an immunocompetent 41-year-old Arab woman who had inflammatory bilateral sciatica L5 and S1 and a history of low back pain caused by a trauma. Radiography, computed tomography, and a vertebral biopsy were useful for diagnosis. She reacted well to anti-bacillary treatment despite the occurrence of multiple paravertebral and subcutaneous abscesses. The medullar magnetic resonance imaging control performed at 4 months, 12 months, and 1 year after the end of treatment showed a favorable evolution. To avoid the delay of diagnosis, especially in our endemic context, tuberculosis must be evoked usually. This will improve the prognosis of our patients.
- Open Access
- 1 April 2014
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 15 (1) , 115
Vitamin D concentrations and disease activity in Moroccan children with juvenile idiopathic arthritis
In addition to its important metabolic activities, vitamin D also contributes to the regulation of the immune system. The aim of this study was to assess the relationship between hypovitaminosis D and disease activity in Moroccan children with juvenile idiopathic arthritis (JIA).
- 1 April 2014
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 15 (1) , 115
Open AccessVitamin D concentrations and disease activity in Moroccan children with juvenile idiopathic arthritis
In addition to its important metabolic activities, vitamin D also contributes to the regulation of the immune system. The aim of this study was to assess the relationship between hypovitaminosis D and disease activity in Moroccan children with juvenile idiopathic arthritis (JIA).